Summary of H.R. 4349: Stop GAPS Act of 2025

Overview

The Stop GAPS Act of 2025 is a bill introduced in the U.S. House of Representatives that aims to address perceived gaps in the government's response to public health emergencies. The bill has a related companion bill, S. 1997, that has been introduced in the Senate.

Purpose and Intent

The main purpose of the Stop GAPS Act is to improve the federal government's ability to rapidly develop, manufacture, and distribute essential medical countermeasures (such as vaccines, treatments, and diagnostics) during public health crises. The bill's supporters argue that gaps in the current system led to delays and shortages during the COVID-19 pandemic, and this legislation is intended to prevent similar problems in future emergencies.

Key Provisions

The Stop GAPS Act would make the following key changes:

1. Establish a Medical Countermeasures Innovation Initiative: This would create a new office within the Department of Health and Human Services (HHS) to coordinate R&D, manufacturing, and distribution of critical medical products during public health emergencies.

2. Require Expanded Stockpiling: The bill mandates that HHS maintain a larger strategic national stockpile of essential medical supplies, including a 6-month supply of certain products.

3. Improve Supply Chain Resilience: The legislation directs HHS to work with the private sector to identify vulnerabilities in supply chains and implement strategies to strengthen them.

4. Enhance Emergency Use Authorization Process: The Stop GAPS Act would streamline the FDA's process for issuing Emergency Use Authorizations for medical countermeasures during crises.

5. Expand Liability Protections: The bill provides liability protection for manufacturers, distributors, and healthcare providers using countermeasures authorized for emergency use.

Potential Impact

If enacted, the Stop GAPS Act could have a significant impact on the government's ability to respond to future public health emergencies. Supporters argue it would help address shortcomings exposed by COVID-19, while critics are concerned about potential overreach or unintended consequences.

The bill would likely affect a wide range of stakeholders, including federal agencies, pharmaceutical and medical supply companies, healthcare providers, and the general public who rely on access to critical medical products during crises.

Timeline and Next Steps

The Stop GAPS Act was introduced in the House on July 10, 2025. It has been referred to the House Committee on Energy and Commerce, which will likely hold hearings and markup sessions before the bill can proceed to a full House vote. Given the bill's bipartisan support, it has a reasonable chance of advancing, but its ultimate fate remains to be seen.